Acceleron Pharma Inc. in brief
Acceleron Pharma Inc. is an unlisted company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It was founded in 2003. In the year to December 2020 it had sales of $93 M and a net loss of $166 M. It employs about 225 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Acceleron Pharma Inc.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Acceleron Pharma Inc. timeline
- 2003
- 🏁· approximateFounded
- 2004
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔· approximateInitial public offering on Nasdaq as XLRN
- 2019
- •Legal Entity Identifier issuedLEI 529900TQRID2UY164805 registered.
Events of Acceleron Pharma Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Acceleron Pharma Inc.
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 22 November 2021 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -179.5%
- Operating margin
- -180.8%
- Return on equity
- -19.4%
- Liabilities / assets
- 8.3%
- Revenue growth
- +25.0%
- R&D / revenue
- 188.0%
- Revenue per employee
- $411 K
- Profit per employee
- $-738 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2020 | $93M | +25.0% | $-167M | $-166M | -179.5% |
| Dec 2019 | $74M | — | $-136M | $-125M | -168.8% |
| Dec 2018 | — | — | $-124M | $-119M | — |
| Dec 2017 | $13M | -51.5% | $-110M | $-108M | -804.5% |
| Dec 2016 | $28M | +53.4% | $-66M | $-57M | -205.3% |
| Dec 2015 | $18M | +23.7% | $-61M | $-64M | -353.0% |
| Dec 2014 | $15M | — | $-55M | $-51M | -350.4% |
| Dec 2013 | — | — | $7M | $-22M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2020 | $-130M | $4M | $-135M | $-2.92 | $0.00 |
| Dec 2019 | $-94M | $3M | $-97M | $-2.38 | $0.00 |
| Dec 2018 | $-95M | $3M | $-97M | $-2.59 | $0.00 |
| Dec 2017 | $-77M | $4M | $-81M | $-2.68 | $0.00 |
| Dec 2016 | $-45M | $3M | $-48M | $-1.52 | $0.00 |
| Dec 2015 | $-44M | $1M | $-45M | $-1.92 | $0.00 |
| Dec 2014 | $-53M | $1M | $-54M | $-1.63 | $0.00 |
| Dec 2013 | $-20M | $0M | $-20M | $-4.15 | — |
SEC filings
- Nov 22, 20218-KCurrent reportAcquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- Nov 4, 202110-QQuarterly report · period to Sep 2021
- Nov 4, 20218-KCurrent reportResults of operations
- Oct 27, 20218-KCurrent reportResults of operations
- Sep 30, 20218-KCurrent reportMaterial agreement · Directors or officers changed · Other events
- Aug 5, 202110-QQuarterly report · period to Jun 2021
- Aug 5, 20218-KCurrent reportResults of operations
- Jul 28, 20218-KCurrent reportResults of operations
- Jun 22, 20218-KCurrent reportRegulation FD disclosure
- Jun 21, 20218-KCurrent reportShareholder vote
- Jun 17, 20218-KCurrent reportOther events
- May 19, 20218-KCurrent reportOther events
Official filings of Acceleron Pharma Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $93 M
- Operating income
- $-167 M
- Net income
- $-166 M
For year ending December-2020 · source: SEC filing
Balance sheet
- Total assets
- $932 M
- Total liabilities
- $77 M
- Total equity
- $855 M
As of December-2020
Top 1 institutional investors in Acceleron Pharma Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Huntington National Bank | 2 | 0 (0.00%) | $0 M | Aug 13, 2026 |
Insider trading at Acceleron Pharma Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joseph S. ZakrzewskiDirector | Tender in a change of control | -34,499 | — | — | 0 | Form 4 |
| filed | Jay T. BackstromEVP, Research and Development | Tender in a change of control | -21,233 | — | — | 0 | Form 4 |
| filed | Sujay KangoEVP, Chief Commercial Officer | Tender in a change of control | -18,509 | — | — | 0 | Form 4 |
| filed | Kemal MalikDirector | Tender in a change of control | -1,622 | — | — | 0 | Form 4 |
| filed | Karen L. SmithDirector | Tender in a change of control | -1,622 | — | — | 0 | Form 4 |
| filed | Terrence C. KearneyDirector | Tender in a change of control | -6,749 | — | — | 0 | Form 4 |
| filed | Kevin F. McLaughlinSVP, CFO and Treasurer | Tender in a change of control | -10,681 | — | — | 0 | Form 4 |
| filed | Francois NaderDirector | Tender in a change of control | -6,749 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Acceleron Pharma Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-4 reverse split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Acceleron Pharma Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (1 of 5). Fiscal year 2020.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 3
- ✓Revenue grew in the newest year25.0%Revenue up 25.0% in fiscal 2020.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.92 vs -2.38Diluted EPS -2.92 in fiscal 2020 against -2.38 the year before (report's currency).
- ✗Net income higher than five years earlier-$166 M-$166 M in fiscal 2020 against -$64 M in 2015.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 5
- ✗Profitable in the newest year-$166 MNet income -$166 M in fiscal 2020.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2020.
- ✗Operating margin above its peers' median-180.8%-180.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-25.4%-25.4% in fiscal 2020.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-180.8%-180.8% in fiscal 2020 against -815.9% in 2017.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities14.8×Current ratio 14.85 at the end of fiscal 2020.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2020.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 2
- ✗Pays a dividendNoNo dividends in fiscal 2020.
- ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2020.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Acceleron Pharma Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 93+25.0%100% | 74+429%100% | 14+3.8%100% | 13−51.5%100% | 28+53.5%100% | 18+23.7%100% | 15−74.4%100% | 57+275%100% | 15−81.1%100% | 81—100% | |
| Research and development | 174+13.0%188% | 154+48.2%208% | 104+15.8%743% | 90+30.8%666% | 69+17.4%247% | 58+14.7%323% | 51+41.2%348% | 36+2.1%63.0% | 35+8.0%232% | 33—40.4% | |
| Selling, general and administrative | 86+52.1%92.9% | 56+63.7%76.3% | 35+2.3%247% | 34—250% | — | — | — | — | — | — | |
| General and administrative | — | — | 35+2.3%247% | 34+33.4%250% | 25+23.0%91.1% | 21+44.9%114% | 14−0.2%97.0% | 14+61.2%24.9% | 8.8+8.4%57.8% | 8.1—10.1% | |
| Total costs and expenses | 260+23.5%281% | 210+52.0%284% | 138+12.1%989% | 123+31.5%916% | 94+18.9%338% | 79+12.7%436% | 70+39.4%479% | 50+13.9%87.9% | 44+4.2%289% | 42—52.3% | |
| Operating income | −167—−181% | −136—−184% | −124—−889% | −110—−816% | −66—−238% | −61—−336% | −55−898%−379% | 7.0—12.1% | −29−175%−189% | 39—47.7% | |
| Interest and finance income | — | — | 5.6+118%39.8% | 2.6+37.7%18.9% | 1.9+262%6.7% | 0.5+517%2.8% | 0.1+113%0.6% | 0.0−57.1%0.1% | 0.1+435%0.6% | 0.0—0.0% | |
| Interest expense and finance costs | — | — | — | — | 0—0.0% | 0−100%0.0% | 0.9−55.9%6.3% | 2.1+36.8%3.7% | 1.5−16.1%10.0% | 1.8—2.3% | |
| Other non-operating income (expense) | 1.3−88.7%1.4% | 12+109%15.6% | 5.5+253%39.4% | 1.6−82.9%11.6% | 9.1—32.8% | −3.0−172%−16.7% | 4.2—28.7% | −29—−50.4% | −3.7—−24.2% | −2.3—−2.8% | |
| Income before tax | −166—−179% | −125—−169% | −119—−850% | −108—−804% | −57—−205% | −64r−64—−353% | −51r−51—−350% | −22—−38.3% | −33−190%−214% | 36—44.9% | |
| Income tax | 0.0—0.0% | −0.1—−0.1% | −0.0−184%−0.2% | 0.0+33.3%0.2% | 0.0—0.1% | 0—0.0% | 0—0.0% | — | — | — | |
| Net income attributable to shareholders | −166—−179% | −125—−169% | −119—−850% | −108—−804% | −57—−205% | −64—−353% | −51—−350% | −22—−38.3% | −33−190%−214% | 36—44.8% | |
| Earnings per share, basic | -2.92—— | -2.38—— | -2.59—— | -2.68—— | -1.52—— | -1.92—— | -1.63—— | -4.15—— | -24.84−3205%— | 0.80—— | |
| Earnings per share, diluted | -2.92—— | -2.38—— | -2.59—— | -2.68—— | -1.52—— | -1.92—— | -1.63—— | -4.15—— | -24.84−3285%— | 0.78—— | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | 9.4+292%— | 2.4+3.1%— | 2.3—— | |
| Shares, weighted average (diluted) | 57+8.3%— | 52+14.3%— | 46+13.6%— | 40+8.0%— | 37+12.4%— | 33+5.7%— | 32+235%— | 9.4+292%— | 2.4−11.6%— | 2.7—— | |
| Dividends per share | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | 0.00—— | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 671+182%72.0% | 238+65.0%47.1% | 144r144+43.8%45.8% | 100+378%25.7% | 21−24.6%8.5% | 28−84.3%19.0% | 176+55.9%94.7% | 113+186%91.5% | 40−39.1%80.5% | 65—— | |
| Short-term investments | 179−7.6%19.2% | 194+31.5%38.4% | 147−16.8%46.8% | 177+49.1%45.5% | 119+54.1%47.9% | 77—52.7% | 0—0.0% | — | — | — | |
| Receivables | — | — | — | — | — | 3.6+7.8%2.5% | 3.4−6.9%1.8% | 3.6+30.3%2.9% | 2.8—5.6% | — | |
| Other current assets | 17+72.6%1.9% | 10+30.5%2.0% | 7.7+72.3%2.4% | 4.4+15.1%1.1% | 3.9+57.1%1.6% | 2.5−0.9%1.7% | 2.5+10.6%1.3% | 2.2+52.2%1.8% | 1.5—3.0% | — | |
| Current assets | 893+98.5%95.8% | 450+47.0%89.1% | 306+7.3%97.2% | 285+94.3%73.3% | 147+32.3%59.3% | 111−39.2%75.8% | 182+53.2%97.9% | 119+171%96.2% | 44—89.1% | — | |
| Property, plant and equipment | 7.8+14.0%0.8% | 6.8−4.1%1.3% | 7.1+2.0%2.3% | 7.0+33.9%1.8% | 5.2+67.5%2.1% | 3.1+0.6%2.1% | 3.1−16.7%1.7% | 3.7−8.7%3.0% | 4.1—8.2% | — | |
| Right-of-use (leased) assets | 22−8.0%2.4% | 24—4.7% | — | — | — | — | — | — | — | — | |
| Long-term investments | 7.6−66.3%0.8% | 22—4.5% | 0−100%0.0% | 96+1.1%24.6% | 95+204%38.2% | 31—21.3% | 0—0.0% | — | — | — | |
| Total assets | 932+84.7%100% | 505+60.4%100% | 315−19.1%100% | 389+57.1%100% | 248+69.2%100% | 146−21.4%100% | 186+50.6%100% | 124+151%100% | 49—100% | — | |
| Accounts payable | 8.5+269%0.9% | 2.3+448%0.5% | 0.4−61.4%0.1% | 1.1−31.7%0.3% | 1.6+81.7%0.6% | 0.9+20.9%0.6% | 0.7−18.2%0.4% | 0.9+37.9%0.7% | 0.6—1.3% | — | |
| Current liabilities | 60+80.3%6.5% | 33+76.5%6.6% | 19+12.9%6.0% | 17+3.7%4.3% | 16+11.4%6.5% | 14+56.6%9.9% | 9.3−66.0%5.0% | 27−29.9%22.0% | 39—78.8% | — | |
| Lease liabilities (non-current) | 17−15.5%1.8% | 20—4.0% | — | — | — | — | — | — | — | — | |
| Total liabilities | 77+39.3%8.3% | 55+143%11.0% | 23−4.9%7.2% | 24+8.7%6.2% | 22−40.5%8.9% | 37+23.5%25.3% | 30−54.5%16.1% | 66−7.9%53.3% | 72—145% | — | |
| Retained earnings | −877—−94.1% | −711—−141% | −587—−186% | −473—−122% | −364—−147% | −307—−210% | −244—−131% | −192—−155% | −291—−591% | — | |
| Shareholders' equity | 855+90.2%91.7% | 449+53.9%89.0% | 292−20.0%92.8% | 365r365+61.9%93.8% | 226+106%91.1% | 109−30.1%74.7% | 156+170%83.9% | 58—46.7% | −291—−591% | −233—— | |
| Total liabilities and equity | 932+84.7%100% | 505+60.4%100% | 315−19.1%100% | 389+57.1%100% | 248+69.2%100% | 146−21.4%100% | 186+50.6%100% | 124+151%100% | 49—100% | — | |
| Shares outstanding | 60+13.7%— | 53+14.8%— | 46+2.2%— | 45+18.3%— | 38+14.8%— | 33+2.7%— | 32r34+14.4%— | 28+1066%— | 2.4—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.8−2.4%4.2% | 3.9+5.2%5.3% | 3.7+32.6%26.8% | 2.8+68.6%21.0% | 1.7+42.5%6.0% | 1.2+5.2%6.5% | 1.1+22.2%7.6% | 0.9−29.2%1.6% | 1.3−58.7%8.5% | 3.1—3.9% | |
| Share-based compensation | 30+31.5%32.7% | 23−6.4%31.1% | 25−13.0%176% | 28+52.2%210% | 19+53.7%66.8% | 12+153%66.7% | 4.8+118%32.7% | 2.2+82.1%3.8% | 1.2−15.5%7.9% | 1.4—1.8% | |
| Cash from operating activities | −130—−141% | −94—−127% | −95—−677% | −77r−77—−568% | −45r−45—−160% | −44—−244% | −53—−364% | −20—−34.3% | −39−529%−255% | 9.1—11.2% | |
| Capital expenditure | −4.2—−4.5% | −3.3—−4.4% | −2.6—−18.5% | −4.4—−32.6% | −3.4—−12.2% | −1.0—−5.3% | −0.5—−3.5% | −0.3—−0.5% | −0.4—−2.9% | −0.0—−0.0% | |
| Cash from investing activities | 26—27.7% | −71−158%−96.3% | 123—879% | −64—−477% | −109—−392% | −109—−602% | −0.5—−3.5% | −0.3—−0.5% | −0.4—−2.9% | −0.0—−0.0% | |
| Debt repaid | — | — | — | — | 0—0.0% | 0—0.0% | −16—−112% | −3.7—−6.4% | −6.2—−40.6% | −9.5—−11.7% | |
| Shares issued | 492+98.5%532% | 248—335% | 0−100%0.0% | 216+53.4%1601% | 141—507% | −0.0r0.6−100%−0.3% | 129r0—883% | 0—0.0% | — | — | |
| Cash from financing activities | 538+108%581% | 259+1502%350% | 16−92.7%115% | 220+50.2%1634% | 147+3156%528% | 4.5−96.2%24.9% | 117+25.2%800% | 94+573%163% | 14−34.1%91.1% | 21—26.1% | |
| Change in cash | 433+363%468% | 94+111%127% | 44−44.1%317% | 79r79—589% | −6.7r−6.8—−24.1% | −149−335%−822% | 63−13.9%433% | 74—129% | −25−184%−167% | 30—37.2% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2021 | Q3 FY2021to Sep 30, 2021 | Q2 FY2021to Jun 30, 2021 | Q1 FY2021to Mar 31, 2021 | Q4 FY2020to Dec 31, 2020 | Q3 FY2020to Sep 30, 2020 | Q2 FY2020to Jun 30, 2020 | Q1 FY2020to Mar 31, 2020 | Q4 FY2019to Dec 31, 2019 | Q3 FY2019to Sep 30, 2019 | Q2 FY2019to Jun 30, 2019 | Q1 FY2019to Mar 31, 2019 | Q4 FY2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 113+6.4%100% | 34+51.6%100% | 28−29.7%100% | 25+470%100% | 26−34.2%100% | 23+436%100% | 40+43.7%100% | 4.3+56.3%100% | 39+931%100% | 4.2—100% | 28—100% | 2.8—100% | 3.8—100% | |
| Research and development | 230+39.2%204% | 60+46.6%175% | 56+46.7%201% | 57+52.1%231% | 57*+17.3%221% | 41+8.3%181% | 38+10.0%96.2% | 38+14.9%867% | 49*+63.4%124% | 38—894% | 35—126% | 33—1179% | 30*—783% | |
| Selling, general and administrative | 138+81.9%122% | 45+114%132% | 35+73.8%127% | 31+70.2%125% | 26*+62.9%101% | 21+35.7%93.3% | 20+45.4%51.4% | 18+68.8%420% | 16*—40.9% | 16—368% | 14—50.7% | 11—389% | — | |
| General and administrative | — | — | — | — | — | — | — | — | — | 16—368% | 14—50.7% | 11—389% | 11*—282% | |
| Total costs and expenses | 368+52.6%327% | 105+69.7%307% | 92+56.1%328% | 88+58.0%357% | 83+28.6%323% | 62+16.3%274% | 59+20.2%148% | 56+28.3%1287% | 65+59.8%165% | 53—1263% | 49—176% | 44—1568% | 41—1065% | |
| Operating income | −255—−227% | −71—−207% | −64—−228% | −64—−257% | −58—−223% | −39—−174% | −19—−47.6% | −52—−1187% | −26—−65.0% | −49—−1163% | −21—−76.4% | −41—−1468% | −37—−965% | |
| Interest and finance income | — | — | — | — | — | — | — | — | — | — | — | — | 1.5*—39.2% | |
| Other non-operating income (expense) | 0.7−78.9%0.6% | 0.2—0.5% | 0.1−68.0%0.5% | 0.1−78.9%0.6% | 0.2*−90.6%0.7% | −0.0−100%−0.0% | 0.5−85.6%1.2% | 0.6−76.6%14.9% | 2.0*−1.6%5.1% | 3.5—83.7% | 3.2—11.7% | 2.8—99.7% | 2.0*—53.3% | |
| Income before tax | −255—−226% | −70—−206% | −64—−227% | −63—−256% | −57*—−222% | −39—−174% | −18—−46.4% | −51—−1172% | −24*—−59.9% | −45—−1079% | −18—−64.7% | −38—−1368% | −35*—−911% | |
| Income tax | 0.0−30.8%0.0% | 0.0+36.4%0.0% | 0.0+100%0.0% | 0.0−66.7%0.0% | −0.0*—−0.0% | 0.0—0.0% | 0.0—0.0% | 0.0−25.0%0.3% | −0.0*—−0.0% | −0.0—−0.8% | −0.0—−0.2% | 0.0—0.7% | −0.0*—−0.9% | |
| Net income attributable to shareholders | −255—−226% | −70—−206% | −64—−227% | −63—−256% | −57—−222% | −39—−174% | −18—−46.4% | −51—−1173% | −24—−59.9% | −45—−1078% | −18—−64.6% | −38—−1369% | −35—−910% | |
| Earnings per share, basic | -4.21—— | -1.16—— | -1.05—— | -1.05—— | -0.95—— | -0.66—— | -0.34—— | -0.95—— | -0.44—— | -0.86—— | -0.34—— | -0.74—— | -0.75—— | |
| Earnings per share, diluted | -4.21—— | -1.16—— | -1.05—— | -1.05—— | -0.95—— | -0.66—— | -0.34—— | -0.95—— | -0.44—— | -0.86—— | -0.34—— | -0.74—— | -0.75—— | |
| Shares, weighted average (basic) | 61+2.2%— | 61+2.2%— | 61+12.7%— | — | — | 60—— | 54—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 61+2.2%— | 61+2.2%— | 61+12.7%— | 61+13.5%— | — | 60+12.8%— | 54+2.2%— | 53+4.4%— | — | 53—— | 53—— | 51—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 336—42.7% | 336−53.9%42.7% | 336+18.6%40.2% | 456+64.2%52.0% | 671+182%72.0% | 730+330%77.0% | 284+73.3%59.1% | 277+29.4%59.8% | 238+65.0%47.1% | 170—32.6% | 164—29.7% | 214—38.3% | 144r144—45.8% | |
| Short-term investments | 254—32.3% | 254+66.4%32.3% | 287+170%34.3% | 232+69.2%26.5% | 179−7.6%19.2% | 153−40.5%16.1% | 106−60.2%22.2% | 137−38.6%29.5% | 194+31.5%38.4% | 257—49.4% | 267—48.5% | 223—39.8% | 147—46.8% | |
| Other current assets | 72—9.1% | 72+711%9.1% | 66+243%8.0% | 25+171%2.9% | 17+72.6%1.9% | 8.9−16.4%0.9% | 19+104%4.0% | 9.3+17.6%2.0% | 10+30.5%2.0% | 11—2.0% | 9.5—1.7% | 7.9—1.4% | 7.7—2.4% | |
| Current assets | 697—88.4% | 697−23.8%88.4% | 718+59.9%85.9% | 738+70.7%84.2% | 893+98.5%95.8% | 914+106%96.4% | 449+0.7%93.6% | 432−3.6%93.1% | 450+47.0%89.1% | 444—85.3% | 446—80.9% | 448—80.0% | 306—97.2% | |
| Property, plant and equipment | 9.4—1.2% | 9.4+23.8%1.2% | 8.6+11.8%1.0% | 7.9+17.8%0.9% | 7.8+14.0%0.8% | 7.6+11.2%0.8% | 7.7+13.2%1.6% | 6.7−5.1%1.4% | 6.8−4.1%1.3% | 6.9—1.3% | 6.8—1.2% | 7.0—1.3% | 7.1—2.3% | |
| Right-of-use (leased) assets | 18—2.3% | 18−6.9%2.3% | 19−11.0%2.2% | 20−9.4%2.3% | 22−8.0%2.4% | 20−22.1%2.1% | 21−20.5%4.4% | 23−19.0%4.9% | 24—4.7% | 25—4.9% | 27—4.8% | 28—5.0% | — | |
| Long-term investments | 62—7.9% | 62+1139%7.9% | 89—10.7% | 108+9534%12.4% | 7.6−66.3%0.8% | 5.0−88.2%0.5% | 0−100%0.0% | 1.1−98.5%0.2% | 22—4.5% | 42—8.1% | 70—12.7% | 76—13.5% | 0—0.0% | |
| Total assets | 788—100% | 788−16.9%100% | 836+74.4%100% | 876+88.7%100% | 932+84.7%100% | 948+82.4%100% | 479−13.0%100% | 464−17.2%100% | 505+60.4%100% | 520—100% | 551—100% | 560—100% | 315—100% | |
| Accounts payable | 5.1—0.6% | 5.1−42.6%0.6% | 9.4−27.0%1.1% | 4.5+13.6%0.5% | 8.5+269%0.9% | 8.9+378%0.9% | 13+264%2.7% | 3.9−0.0%0.8% | 2.3+448%0.5% | 1.9—0.4% | 3.5—0.6% | 3.9—0.7% | 0.4—0.1% | |
| Current liabilities | 57—7.3% | 57+53.8%7.3% | 59+59.2%7.1% | 50+74.6%5.7% | 60+80.3%6.5% | 37+17.9%3.9% | 37+43.4%7.8% | 29+22.6%6.1% | 33+76.5%6.6% | 32—6.1% | 26—4.7% | 23—4.2% | 19—6.0% | |
| Lease liabilities (non-current) | 12—1.5% | 12−22.0%1.5% | 13−22.3%1.6% | 15−18.2%1.7% | 17−15.5%1.8% | 15−29.9%1.6% | 17−27.6%3.5% | 19−25.7%4.0% | 20—4.0% | 22—4.2% | 23—4.2% | 25—4.4% | — | |
| Total liabilities | 70—8.8% | 70+32.4%8.8% | 73+26.3%8.7% | 65+29.0%7.4% | 77+39.3%8.3% | 53−4.1%5.6% | 58+13.4%12.1% | 50+1.1%10.8% | 55+143%11.0% | 55—10.6% | 51—9.3% | 50—8.9% | 23—7.2% | |
| Retained earnings | −1,075—−136% | −1,075—−136% | −1,004—−120% | −941—−107% | −877—−94.1% | −820—−86.5% | −781—−163% | −762—−164% | −711—−141% | −688—−132% | −642—−117% | −625—−111% | −587—−186% | |
| Shareholders' equity | 718—91.2% | 718−19.8%91.2% | 763+81.0%91.3% | 811+95.9%92.6% | 855+90.2%91.7% | 895+92.6%94.4% | 422−15.7%87.9% | 414−18.9%89.2% | 449+53.9%89.0% | 465—89.4% | 500—90.7% | 511—91.1% | 292—92.8% | |
| Total liabilities and equity | 788—100% | 788−16.9%100% | 836+74.4%100% | 876+88.7%100% | 932+84.7%100% | 948+82.4%100% | 479−13.0%100% | 464−17.2%100% | 505+60.4%100% | 520—100% | 551—100% | 560—100% | 315—100% | |
| Shares outstanding | 61—— | 61+1.8%— | 61+12.2%— | 61+13.3%— | 60+13.7%— | 60+13.2%— | 54+2.7%— | 54+1.9%— | 53+14.8%— | 53—— | 53—— | 53—— | 46—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 4.2+9.8%3.7% | 1.2*+28.5%3.4% | 1.0*+10.0%3.7% | 1.0+3.0%4.1% | 1.0*−0.5%3.9% | 0.9*−8.8%4.0% | 0.9*−6.6%2.4% | 1.0+6.8%22.9% | 1.0*+14.8%2.6% | 1.0*—23.5% | 1.0*—3.6% | 0.9r2.2—33.6% | 0.9*—23.0% | |
| Share-based compensation | 49+78.1%43.4% | 11+43.0%33.4% | 13+88.8%48.2% | 16+134%63.1% | 8.4*+48.3%32.6% | 8.0+50.5%35.4% | 7.1+42.5%18.0% | 6.7−4.5%154% | 5.7*−12.6%14.5% | 5.3—126% | 5.0—18.1% | 7.0—252% | 6.5*—171% | |
| Cash from operating activities | −261—−232% | −71*—−207% | −84*—−302% | −68—−274% | −38*—−147% | −2.8*—−12.4% | −43*—−108% | −47—−1071% | −16*—−41.3% | −37*—−880% | −14*—−51.3% | −26—−946% | −29*—−761% | |
| Capital expenditure | −5.2—−4.6% | −2.4*—−7.0% | −1.0*—−3.5% | −0.9—−3.7% | −0.9*—−3.5% | −0.9*—−3.9% | −2.0*—−5.0% | −0.4—−9.8% | −1.1*—−2.8% | −0.9*—−21.2% | −0.7*—−2.5% | −0.6—−21.1% | −0.7*—−18.1% | |
| Cash from investing activities | −161−218%−143% | 57*—166% | −37*−224%−133% | −151−295%−611% | −30*−136%−114% | −52*−238%−232% | 30*—75.3% | 77—1784% | 82*+36.7%208% | 38*—903% | −38*—−139% | −153—−5488% | 60*—1566% | |
| Shares issued | — | — | — | — | 0*—0.0% | 492*—2183% | 0*—0.0% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−0.1% | 248—8926% | 0*—0.0% | |
| Cash from financing activities | 29−94.5%25.8% | 14*−97.2%41.4% | 2.2*−88.2%8.0% | 3.7−58.3%14.9% | 9.0*+237%34.8% | 501*+9930%2221% | 19*+993%47.7% | 8.9−96.4%204% | 2.7*+202%6.8% | 5.0*—119% | 1.7*—6.3% | 249—8968% | 0.9*—23.2% | |
| Change in cash | −393−170%−349% | 0.1*−100.0%0.2% | −119*−2077%−427% | −215−641%−870% | −59*−186%−227% | 446*+7420%1978% | 6.0*—15.2% | 40−43.5%916% | 68*+115%173% | 5.9*—141% | −51*—−184% | 70—2534% | 32*—829% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2021. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Acceleron Pharma Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 22, 2021
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Acceleron Pharma Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2022, most often on medicare/medicaid, health issues and taxation/internal revenue code.
- Medicare/Medicaid1 report
- Health Issues1 report
- Taxation/Internal Revenue Code1 report
Lobbying firms hired in 2022
SPLITOAK STRATEGIES LLC $30 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $30 K | — | 1 |
| 2021 | $84 K | $60 K | 10 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Acceleron Pharma”, “Acceleron Pharma, Inc” and “ACCELERON PHARMA INC”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Acceleron Pharma Inc.#
5 labor condition applications certified in fiscal 2021 for 5 positions, at a median wage of $102 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist I, Protein Biochemistry - DiscoveryBiochemists and Biophysicists | 2 | $86 K |
| Clinical Research Outsourcing ManagerNatural Sciences Managers | 1 | $146 K |
| Senior Associate, Regulatory AffairsRegulatory Affairs Specialists | 1 | $110 K |
| Senior Quality Control Analyst IChemists | 1 | $102 K |
Where: Cambridge, MA 5
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2021 | 5 | 5 | $102 K | 5 |
| FY2020 | 1 | 1 | $70 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Acceleron Pharma Inc.
How Acceleron Pharma Inc. compares in Biotechnology
- Revenue$93 M · higher than 68% of 647
- Net margin-179.4% · higher than 30% of 408
- Revenue growth25.0% · higher than 64% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Acceleron Pharma Inc.🇺🇸 | — | — | -179.4% | +25.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2020
- Balance sheet:
- As of December-2020
- Employees:
- As of December 2019
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, Wikidata, Wikipedia, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Acceleron Pharma Inc.? Verify and update this profile — free
Show Acceleron Pharma Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.